Earlier evaluations have estimated cost-effectiveness of different endocrine therapies and conventional aromatase inhibitors in first-line treatment of post-menopausal women.9–12 But no study has yet carried out a cost-effectiveness comparison of two CDK inhibitors in post-menopausal women with advanced breast cancer in the UK. Here, CYP19A1 is linked to breast cancer.